Skip to main content

Table 3 Baseline scores and changes from baseline in efficacy outcome measures at weeks 24, 48 and 80 [Mean (SD)].

From: Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators

Measure

Baseline

Week 24

Week 48

Week 80

 

N = 75

N = 73

N = 57

N = 45

UHDRS Motor Score

47.9 (15.9)

-7.4 (9.8) *

-5.6 (12.1) *

-0.2 (11.0)

Total Chorea

14.9 (3.7)

-5.8 (5.0) *

-5.6 (5.5) *

-4.6 (5.5) *

Gait

1.3 (0.6)

-0.1 (0.6)

0.0 (0.7)

0.2 (0.7)

Parkinsonism

14.5 (5.7)

-0.5 (2.7)

0.9 (4.1)

2.1 (4.3) *

Barnes Akathisia

0.2 (0.6)

0.1 (1.0)

0.1 (0.9)

0.0 (0.7)

Hamilton

4.1 (3.7)

-0.0 (3.8)

0.7 (3.4)

0.4 (3.8)

Functional Checklist

18.1 (4.7)

-0.3 (2.5)

-1.1 (2.3) *

-2.6 (3.3) *

Independence

75.7 (11.5)

-2.4 (7.2) *

-4.4 (6.0) *

-7.0 (8.1) *

Behavioral Score (freq*severity)

6.7 (9.7)

3.4 (14.4) *

2.9 (9.3) *

3.5 (14.4)

Weight (kg)

72.4 (18.8)

-1.2 (4.8) *

-1.4 (7.4)

-1.7 (6.5)

 

N = 47

N = 45

N = 38

N = 30

Total Functional Capacity

7.6 (2.4)

-0.5 (1.5) *

-1.1 (1.4) *

-2.0 (2.3) *

Verbal

17.2 (10.3)

-2.0 (5.6) *

-2.0 (5.8) *

-3.6 (7.9) *

Symbol Digit

19.3 (11.2)

-0.3 (5.5)

-1.9 (4.7) *

-4.8 (10.3) *

Stroop Color

42.6 (17.3)

-4.4 (9.5) *

-8.9 (11.4) *

-11.0 (14.8) *

Stroop Words

49.8 (20.6)

-1.2 (9.3)

-7.9 (15.4) *

-9.0 (17.4) *

Stroop Interference

23.2 (11.4)

-2.7 (7.1) *

-4.5 (7.0) *

-5.0 (10.4) *

  1. * p < 0.05 (t-test)